You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Olfactory dysfunction, also known as anosmia and hyposmia, is one of the most prevalent (80-90%) symptoms reported by patients with COVID-19. Outside the context of COVID-19, chemosensory dysfunction has been associated with decreased quality of life, anxiety, depression, and cognitive impairment. In the setting of COVID-19, decreased sense of smell has been positively associated with mood disorders such as anxiety and depression. The short-term and long-term neuropsychiatric implications of the olfactory dysfunction related to COVID-19 are still largely unexplored. Investigation of the neuropsychiatric sequelae of olfactory dysfunction related to COVID-19 infection is particularly critical to characterize the pathological effects of COVID-19 on brain function and to develop strategies to improve patient’s quality of life and mental wellbeing. In this Research Topic, Frontiers aims to highlight studies that investigate the neuropsychiatric, psychological, and cognitive consequences of COVID-19-related olfactory dysfunction, present current advances in the field, and anticipate health care needs for the development of therapeutic interventions.
This Research Topic is part of the Ferroptosis in Stroke, Neurotrauma and Neurodegeneration series: Ferroptosis in Stroke, Neurotrauma and Neurodegeneration Ferroptosis is a recently defined iron-dependent non-apoptotic form of cell death. Diverse stressors can destabilize metabolic processes in the cell, leading to excessive intracellular accumulation of reactive oxygen species that culminate in the collapse and rupture of the membrane structure of cellular organelles, such as mitochondria, endoplasmic reticulum, and lysosome. Ferroptosis is a form of cell death characterized by the accumulation of intracellular iron and lipid ROS. The primary morphologic manifestations of ferroptosis inclu...